Integrated Drug Discovery Services: Advancing the Journey From Target to Candidate

Discovering a new therapeutic molecule is a complex scientific process that requires expertise across chemistry, biology, pharmacology, computational science, and drug metabolism. Because these disciplines are closely connected, coordination between research teams can be an important part of progressing a discovery program.

Integrated drug discovery services bring multiple scientific capabilities together to support the journey from target evaluation and hit identification through lead optimization and candidate selection.

Building a Strong Foundation With Target Validation

A drug discovery program often begins with understanding whether a biological target has a meaningful relationship with a disease.

Target validation can involve biochemical, cellular, genetic, and disease-relevant studies. Establishing this connection provides researchers with information that can guide subsequent screening and compound discovery activities.

A well-defined target strategy can also help researchers determine which discovery tools and experimental models are appropriate for the program.

Identifying Promising Hits

Once a target has been established, researchers can investigate molecules that may interact with it.

Hit identification can involve several complementary approaches, including experimental screening, virtual screening, computational molecular design, and fragment-based discovery. Structural information can also help researchers understand how molecules interact with their targets.

The objective is to identify promising starting points for further investigation rather than simply generating a large number of compounds.

Transforming Hits Into Leads

Initial hits generally require optimization before they can be considered suitable lead compounds. Medicinal chemistry teams can modify molecular structures while biology teams evaluate changes in potency, selectivity, and mechanism.

Computational chemistry and structural biology can contribute additional insights into molecular interactions and guide subsequent design cycles.

This iterative process of designing, synthesizing, and testing compounds is central to many discovery programs.

Combining Chemistry With DMPK

A compound's biological activity is only one aspect of its development potential. Researchers also need to understand how a molecule behaves in biological systems.

DMPK studies can provide information about metabolism, exposure, pharmacokinetics, and other properties that influence compound progression. Integrating this information with medicinal chemistry and pharmacology can help researchers evaluate compounds more comprehensively.

This multidisciplinary interaction is one of the important features of an integrated discovery model.

Preparing for Candidate Selection

As lead optimization progresses, research teams evaluate compounds against multiple criteria. Potency, selectivity, pharmacokinetics, safety-related properties, and other characteristics can influence which molecules warrant further development.

An integrated workflow allows information from different scientific disciplines to be considered together during these decisions.

Companies exploring Integrated drug discovery services can access a coordinated approach covering key stages of the discovery process. Jubilant Biosys describes its workflow as spanning target validation, hit identification, lead optimization, and preclinical candidate selection. 

The Value of Cross-Functional Collaboration

Drug discovery programs generate information from many different experimental systems. Keeping chemistry, biology, pharmacology, structural biology, and DMPK teams connected can help researchers interpret these datasets in context.

For example, structural information may influence medicinal chemistry decisions, while pharmacokinetic findings can lead to changes in molecular design. This continuous exchange of information supports an iterative discovery process.

Flexible Discovery Partnerships

Not every pharmaceutical company requires the same level of external support. Some programs may need an end-to-end discovery solution, while others may require expertise in specific areas such as computational chemistry, medicinal chemistry, screening, pharmacology, or DMPK.

Jubilant Biosys states that it offers flexible engagement models, including integrated programs, milestone and hybrid models, FTE-based models, and fee-for-service arrangements. 

From Discovery to Preclinical Development

The transition from lead optimization toward preclinical development requires continued evaluation of a compound's properties. An integrated approach can help maintain scientific continuity as promising molecules progress toward candidate selection.

Jubilant Biosys currently describes its broader discovery-to-development framework as including target validation, hit identification, lead optimization, preclinical candidate selection, and preclinical development. 

Conclusion

Modern drug discovery depends on collaboration between multiple scientific disciplines. Integrated drug discovery services provide a framework for connecting target validation, screening, medicinal chemistry, structural biology, DMPK, pharmacology, and candidate selection.

By bringing complementary expertise into a coordinated workflow, integrated discovery programs can support pharmaceutical and biotechnology research teams as they progress promising molecules from early target research toward preclinical development.